LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Stoelzle – 15th May 2025

Biogen, AbbVie jointly pull MS drug from the market

The decision to pull Zinbryta followed cases of encephalitis, inflammation of the brain, and meningoencephalitis, which simultaneously resembles meningitis and encephalitis.

Biogen (BIIB) and AbbVie (ABBV) have announced they are pulling their jointly developed multiple sclerosis drug Zinbryta from the market following reports of brain inflammation in patients using the medication.
However, Biogen will not have much material impact because of this decision as Zinbryta was expected to bring in about $400 million in 2027 revenue for the company, or less than 3% of total sales. Biogen has a suite of multiple sclerosis drugs.
Zinbryta is tied to liver toxicity, inflammatory/immune toxicity and cases of hypersensitivity. The decision to pull Zinbryta followed cases of encephalitis, inflammation of the brain, and meningoencephalitis, which simultaneously resembles meningitis and encephalitis.
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025
Drug Discovery 2025, ELRIG – 04.07.2025